

# Largest GWAS (N=1,126,563) of Alzheimer's Disease Implicates Microglia and Immune Cells

## Author List and affiliations

Douglas P Wightman<sup>1</sup>, Iris E Jansen<sup>1</sup>, Jeanne E. Savage<sup>1</sup>, Alexey A Shadrin<sup>2</sup>, Shahram Bahrami<sup>2-4</sup>, Arvid Rongve<sup>5,6</sup>, Sigrid Børte<sup>3,7,8</sup>, Bendik S Winsvold<sup>8-10</sup>, Ole Kristian Drange<sup>11,12</sup>, Amy E Martinsen<sup>3,8,9</sup>, Anne Heidi Skogholt<sup>8,13</sup>, Cristen Willer<sup>14</sup>, Geir Bråthen<sup>15-17</sup>, Ingunn Bosnes<sup>11,18</sup>, Jonas Bille Nielsen<sup>8,14,19</sup>, Lars Fritsche<sup>20</sup>, Laurent F. Thomas<sup>8,13</sup>, Linda M Pedersen<sup>9</sup>, Maiken E Gabrielsen<sup>8</sup>, Marianne Bakke Johnsen<sup>3,7,8</sup>, Tore Wergeland Meisingset<sup>15,16</sup>, Wei Zhou<sup>21,22</sup>, Petra Proitsi<sup>23</sup>, Angela Hodges<sup>23</sup>, Richard Dobson<sup>23-25</sup>, Latha Velayudhan<sup>23</sup>, 23andMe Research Team<sup>26</sup>, Julia M Sealock<sup>27,28</sup>, Lea K Davis<sup>27-29</sup>, Nancy L. Pedersen<sup>30</sup>, Chandra A. Reynolds<sup>31</sup>, Ida K. Karlsson<sup>30,32</sup>, Sigurdur Magnusson<sup>33</sup>, Hreinn Stefansson<sup>33</sup>, Steinunn Thordardottir<sup>34</sup>, Palmi V. Jonsson<sup>34</sup>, Jon Snaedal<sup>34</sup>, Anna Zettergren<sup>35</sup>, Ingmar Skoog<sup>35,36</sup>, Silke Kern<sup>35,36</sup>, Margda Waern<sup>35,37</sup>, Henrik Zetterberg<sup>38-41</sup>, Kaj Blennow<sup>40,41</sup>, Eystein Stordal<sup>11,18</sup>, Kristian Hveem<sup>8,42</sup>, John-Anker Zwart<sup>3,8,9</sup>, Lavinia Athanasiu<sup>2,4</sup>, Ingvild Saltvedt<sup>15,17</sup>, Sigrid B Sando<sup>15,16</sup>, Ingun Ulstein<sup>43</sup>, Srdjan Djurovic<sup>2</sup>, Tormod Fladby<sup>3</sup>, Dag Aarsland<sup>23,44,45</sup>, Geir Selbæk<sup>3,43,46</sup>, Stephan Ripke<sup>22,47,48</sup>, Kari Stefansson<sup>33</sup>, Ole A. Andreassen<sup>2,4,49</sup>, Danielle Posthuma<sup>1,50\*</sup>

1. *Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam, The Netherlands.*
2. *NORMENT Centre, University of Oslo, Oslo, Norway.*
3. *Institute of Clinical Medicine, University of Oslo, Oslo, Norway.*
4. *Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.*
5. *Department of Research and Innovation, Helse Fonna, Haugesund Hospital, Haugesund, Norway.*
6. *The University of Bergen, Institute of Clinical Medicine (K1), Bergen Norway.*
7. *Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.*
8. *K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.*
9. *Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.*
10. *Department of Neurology, Oslo University Hospital, Oslo, Norway.*
11. *Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.*
12. *Division of Mental Health Care, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.*
13. *Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.*
14. *Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, 48109, MI, USA.*
15. *Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.*
16. *Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Norway.*
17. *Department of Geriatrics, St. Olav's Hospital, Trondheim University Hospital, Norway.*

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18. *Department of Psychiatry, Hospital Namsos, Nord-Trøndelag Health Trust, Namsos, Norway.*
19. *Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.*
20. *Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, 48109, MI, USA.*
21. *Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.*
22. *Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.*
23. *Institute of Psychiatry, Psychology and Neurosciences, King's College London.*
24. *NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at 16 South London and Maudsley NHS Foundation, London, UK.*
25. *Farr Institute of Health Informatics Research, UCL Institute of Health Informatics.*
26. *23andMe, Inc., Mountain View, CA, USA.*
27. *Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville, TN, 37232, USA.*
28. *Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.*
29. *511-A Light Hall, Vanderbilt University Medical Center, 2215 Garland Ave Nashville, TN 37232.*
30. *Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.*
31. *Department of Psychology, University of California-Riverside, Riverside, CA, USA.*
32. *Institute of Gerontology and Aging Research Network – Jönköping (ARN-J), School of Health and Welfare, Jönköping University, Jönköping, Sweden.*
33. *deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.*
34. *Department of Geriatric Medicine, Landspítali University Hospital, Reykjavik, Iceland.*
35. *Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Sweden.*
36. *Region Västra Götaland, Sahlgrenska University Hospital, Psychiatry, Cognition and Old Age Psychiatry Clinic, Gothenburg, Sweden.*
37. *Region Västra Götaland, Sahlgrenska University Hospital, Psychosis Clinic, Gothenburg, Sweden.*
38. *Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.*
39. *UK Dementia Research Institute at UCL, London, United Kingdom.*
40. *Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.*
41. *Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.*
42. *HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.*
43. *Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.*
44. *Centre of Age-Related Medicine, Stavanger University Hospital, Norway.*
45. *Institute of Psychiatry, Psychology & Neuroscience, PO 70, 16 De Crespigny Park, London, SE58AF.*
46. *Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.*
47. *Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.*
48. *Department of Psychiatry and Psychotherapy, Charité–Universitätsmedizin, Berlin,*

Germany.

49. Oslo University Hospital, Kirkeveien 166, 0407 Oslo, Norway.

50. Department of Child and Adolescent Psychiatry and Pediatric Psychology, Section Complex Trait Genetics, Amsterdam Neuroscience, Vrije Universiteit Medical Center, Amsterdam University Medical Center, Amsterdam, The Netherlands

\*Correspondence should be addressed to: Danielle Posthuma: Department of Complex Trait Genetics, VU University, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands. Phone: +31 20 598 2823, Fax: +31 20 5986926, d.posthuma@vu.nl

**Word count:** Summary: 196; main text: 2447

**Display items:** 3 (Tables 1, Figures 2)

Includes **Online Methods, Supplementary Information** and **Supplementary Tables 1-15**

## Summary

Late-onset Alzheimer's disease is a prevalent age-related polygenic disease that accounts for 50-70% of dementia cases<sup>1</sup>. Late-onset Alzheimer's disease is caused by a combination of many genetic variants with small effect sizes and environmental influences. Currently, only a fraction of the genetic variants underlying Alzheimer's disease have been identified<sup>2,3</sup>. Here we show that increased sample sizes allowed for identification of seven novel genetic loci contributing to Alzheimer's disease. We highlighted eight potentially causal genes where gene expression changes are likely to explain the association. Human microglia were found as the only cell type where the gene expression pattern was significantly associated with the Alzheimer's disease association signal. Gene set analysis identified four independent pathways for associated variants to influence disease pathology. Our results support the importance of microglia, amyloid and tau aggregation, and immune response in Alzheimer's disease. We anticipate that through collaboration the results from this study can be included in larger meta-analyses of Alzheimer's disease to identify further genetic variants which contribute to Alzheimer's pathology. Furthermore, the increased understanding of the mechanisms that mediate the effect of genetic variants on disease progression will help identify potential pathways and gene-sets as targets for drug development.

## Main text

Dementia has an age- and sex- standardised prevalence of ~7.1% in Europeans<sup>4</sup>, with Alzheimer's disease (AD) being the most common form of dementia (50-70% of cases)<sup>1</sup>. AD is pathologically characterized by the presence of amyloid-beta plaques and tau neurofibrillary tangles in the brain<sup>5</sup>. Most patients are diagnosed with AD after the age of 65, termed late onset AD (LOAD), while only 1% of the AD cases have an early onset (before the age of 65)<sup>5</sup>. Based on twin studies, the heritability of LOAD is estimated to be ~60-80%<sup>6,7</sup>, suggesting that a large proportion of individual differences in LOAD risk is driven by genetics. The heritability of LOAD is spread across many genetic variants; however, Zhang *et al.* (2020)<sup>2</sup> suggested that LOAD is more of an oligogenic than polygenic disorder due to the large effects of *APOE* variants. According to Zhang *et al.* (2020) and Holland *et al.* (2020)<sup>3</sup> there are predicted to be ~100-1000 causal variants contributing to LOAD and only a fraction have been identified. Increasing the sample size of GWAS studies will improve the statistical power to identify the missing causal variants and may highlight novel disease mechanisms.

The largest previous GWAS of LOAD, performed in 2019, identified 29 risk loci from 71,880 (46,613 proxy) cases and 383,378 (318,246 proxy) controls<sup>8</sup>. Our current study

expands this to include 90,338 (46,613 proxy) cases and 1,036,225 (318,246 proxy) controls. The recruitment of LOAD cases can be difficult due to the late age of onset so proxy cases can allow for the inclusion of younger individuals by estimating their risk of LOAD using parental status. In the current study, we identified 38 loci, including seven loci that have not been reported previously. Extensive functional follow-up analyses implicated tissues, cell types, and genes of interest through tissue and cell type enrichment, colocalization, and statistical fine-mapping. This study highlights microglia, immune cells, and protein catabolism as relevant to LOAD while identifying novel genes of potential interest.

## Genome-wide inferences

We meta-analyzed data from 13 cohorts, totaling 1,126,563 individuals (**Supplementary Table 1**). Proxy cases and controls were defined based on known parental LOAD status weighted by parental age (**Online Methods**). The meta-analysis identified 3915 significant ( $P < 5 \times 10^{-8}$ ) variants across 38 independent loci (**Table 1, Figure 1**). Of those 38 loci, seven have not shown associations with LOAD in previous GWAS, and five of those novel loci have not been associated with any form of dementia. Three of the seven novel loci are inconclusive due to low support from surrounding variants (**Supplementary Results**). In comparison to our previous meta-analysis<sup>8</sup>, we failed to replicate the association of *ADAMTS4*, *HESX1*, *CNTNAP2*, *KAT8*, *SCIMP*, *ALPK2*, and *AC074212.3* in the current study.

One novel locus (*NTN5* locus) was relatively close to the *APOE* locus (within 2.7Mb) and thus could be influenced by the strong association signal of *APOE*. However, we used GCTA-COJO<sup>9</sup> to identify independently associated variants and found the *NTN5* region to be unaffected when conditioning on the *APOE* region (**Supplementary Results**), suggesting this *NTN5* locus is a LOAD risk factor independent from *APOE*.

The liability-scale SNP heritability was estimated by linkage disequilibrium score (LDSC) regression<sup>10</sup> to be 0.025 (SE=0.0043) given a population prevalence of 0.05 (*APOE* region excluded). This estimate is low but similar to the estimate obtained in a previous GWAS meta-analysis ( $h_{21} = 0.055$ , SE=0.0099)<sup>8</sup>. The genetic correlation<sup>11</sup> between proxy LOAD and case-control LOAD was estimated at 0.83 (SE=0.21,  $P = 6.61 \times 10^{-5}$ ). Separate Manhattan plots for the LOAD proxy data and the case-control LOAD data are available in the Supplementary Results (**Supplementary Figures 1 & 2**). Across 855 external phenotypes in LDhub<sup>12</sup>, two significant genetic correlations with the meta-analysis results were observed (**Supplementary Table 2**). The strongest correlation was with a previous LOAD study conducted by Lambert *et al.* (2013)<sup>13</sup> ( $r_g = 1.18$ , SE=0.19,  $P_{Bonferroni} = 2.42 \times 10^{-7}$ ). The other significant correlation was with the UK Biobank (UKB)<sup>14</sup> trait "Illnesses of mother: Alzheimer's disease/dementia" ( $r_g = 0.80$ , SE=0.11,  $P_{Bonferroni} = 6.38 \times 10^{-10}$ ). The current study included individuals which are also included in Lambert *et al.* (2013)<sup>13</sup> and the UKB.

## Tissue type, cell type, and gene set enrichment

MAGMA tissue specificity analysis<sup>15</sup> identified spleen ( $P_{Bonferroni} = 0.034$ ) as the GTEx tissue where expression of the significant MAGMA genes was enriched (**Supplementary Figure 2, Supplementary Table 3**). Spleen was also significant in the previous MAGMA tissue specificity analysis performed in Jansen *et al.* (2019)<sup>8</sup> and is a known contributor to immune function. To investigate enrichment at the cell type level, FUMA cell type analysis<sup>16</sup> was performed with a collection of cell types in mouse brain, human brain, and human blood tissue, resulting in 6 single-cell (scRNA-seq) datasets significantly associated, after multiple testing correction ( $P < 5.39 \times 10^{-5}$ ), with the expression of LOAD-associated genes (**Supplementary Figure 4, Supplementary Table 4**). The only significant cell type in all six

independent scRNA datasets was microglia. Human microglia have not been previously identified in cell type analysis for LOAD. A combination of the cell type and tissue specificity results identifies microglia and immune tissues as potential experimental models for identifying the contribution of LOAD-associated genes towards LOAD pathogenesis. MAGMA gene set analysis<sup>15</sup> identified 25 Gene Ontology biological process (**Supplementary Table 5**) that were significantly enriched, after multiple testing correction ( $P < 3.23 \times 10^{-6}$ ), for LOAD-associated variants. Subsequent conditional gene set analyses confirmed independent association of four out of these 25 gene-sets, reflecting the role of LOAD-associated genes in amyloid and tau plaque formation, protein catabolism of plaques, immune cell recruitment, and glial cells (**Supplementary Table 5**).

## Implicated Genes

Functional mapping of variants to genes based on position and expression quantitative trait loci (eQTL) information from brain and immune tissues/cells identified 989 genes mapped to one of the 38 genomic risk loci (**Supplementary Table 6**). Although the causal gene is not certain (see **Supplementary Results**), one of the positionally mapped genes (*ITGA2B*) within a novel locus (locus 28) is a potential drug target for LOAD treatment. The protein encoded by *ITGA2B* is a target for Abciximab, an antibody which inhibits platelet aggregation and is used to estimate concentrations of coated-platelets<sup>17</sup>. In patients with mild cognitive impairments, elevated coated-platelet levels are linked to increased risk of LOAD progression, and might constitute a relevant target for the mitigation of LOAD development.

Due to linkage disequilibrium (LD) and the inability to distinguish true causal variants from variants in LD, many of the mapped genes may be functionally irrelevant to LOAD. In order to highlight potentially relevant genes, eQTL data from immune tissues, brain, and microglia were colocalized with the genomic risk loci using Coloc<sup>18</sup>. We found 16 successful colocalizations for eight genes: *MADD*, *APH1B*, *GRN*, *AC004687.2*, *ACE*, *NTN5*, *CD33*, and *CASS4* (**Supplementary Table 7**). One notable borderline result was the colocalization of microglia eQTL data for *BIN1* with locus 4 with a posterior probability of 0.78. This result is notable because *BIN1* is a well-established LOAD risk gene<sup>19</sup> and microglia appear to be enriched with expression of LOAD genes.

## Credible causal variants

Some loci were large and contained numerous genes, complicating identification of the causal variants and genes. Statistical fine-mapping with FINEMAP<sup>20</sup> and SusieR<sup>21</sup> narrowed down the signal to a smaller number of variants with the greatest probability to explain the association signal. Across the 36 fine-mapped loci (*APOE* and *HLA-DRB1* (MHC) loci were excluded due to complex LD) there were 386,521 variants; after fine-mapping there were 3822 unique variants across the FINEMAP<sup>20</sup> 95% confidence set and the SusieR<sup>21</sup> credible sets (hereafter “credible causal variants”). The median number of credible causal variants per locus was 74 and the median number of variants per locus that were included in the fine-mapping analysis was 11046. This represents a large reduction in the number of variants within a region. Full results of the fine-mapping are available in **Supplementary Table 8**.

## Active chromatin enrichment

All the variants included in the fine-mapping analyses (hereafter “mapping region”) were annotated as being in active or inactive chromatin across 127 cell types based on the ROADMAP Core 15-state model<sup>22</sup>. In all cell types, the credible causal variants were significantly enriched in active chromatin compared to the other variants included in the mapping region (**Supplementary Table 9**). As these analyses make comparisons amongst

variants within genomic risk loci, which were shown to be enriched in active chromatin regions (**Supplementary Results**), this shows that credible causal variants harbor even greater potential for functional consequences. Cell types with credible causal variants most enriched for active chromatin included immune cells, brain tissue, and induced pluripotent cells derived from fibroblasts (iPS DF 19.11) (**Supplementary Figure 5**). The inclusion of immune cells in the top enriched cell types supports the findings from the genomic risk loci enrichment and again highlights immune genetics as important for LOAD.

### eQTL enrichment

The variants within the mapping region were annotated with eQTL information from 46 GTEx v8 tissues. All tissue types were significantly enriched with eQTLs in credible causal variants compared to the mapping region (ORs 3.70-28.60) (**Supplementary Table 10**). The large proportion and enrichment of eQTLs across all tissues in the credible causal variants compared to the mapping region highlights eQTLs as possible agents in driving the association signal. The pattern of enrichment did not appear to highlight any specific tissues of interest; rather it reflected the proportion of eQTLs within the credible causal variants. The cell types with the highest proportion of eQTLs in the credible causal variants tend to have the lowest enrichments and vice versa.

### Functional consequence enrichment

The variants within the mapping region were annotated for functional consequence as well as an estimate of deleteriousness (CADD score<sup>23</sup>) to determine whether the credible causal variants were enriched for an effect on genes (**Supplementary Table 11**). All annotations which imply proximity to genes were significantly enriched, except TF binding site and 5' UTR (**Figure 2**). The only annotation which implies distance to genes (intergenic variants) was significantly depleted (OR=0.32, Prop=0.12,  $P_{Bonferroni}=7.54 \times 10^{-152}$ ). The most enriched variant annotation was synonymous variants (OR=2.36, Prop=0.018,  $P_{Bonferroni}=1.14 \times 10^{-8}$ ). Missense variants were slightly enriched (OR=1.51, Prop=0.016,  $P_{Bonferroni}=0.037$ ) and variants with CADD score > 15 were not significantly enriched. Of the 54 significant missense variants within the genomic risk loci, 29 were included in the fine-mapping region, however only 9 were identified in the fine-mapping credible sets. The relative lack of missense variant and CADD score (>15) enrichment combined with the high proportion and enrichment of eQTLs within the credible causal variants suggests that the association signal in the current study is largely driven through gene expression modulation rather than protein coding changes. This could be due to a true causal effect of eQTLs on LOAD pathology or due our focus on common variants which are less likely to be highly deleterious missense variants.

## Discussion

We performed the largest GWAS for LOAD to date, including 1,126,563 individuals, and identified 38 LOAD-associated loci, including seven novel loci. The data included both clinical cases and proxy cases, defined based on parental LOAD status, a strategy that was validated previously by us<sup>8</sup> and others<sup>24</sup>. Through gene set analysis, tissue and single cell specificity analysis, colocalization, fine-mapping, and enrichment analyses, this study highlighted novel biological routes that connect genetic variants to LOAD pathology. These functional analyses all implicated immune cells and microglia as cells of interest which provided genetic support to the current understanding of LOAD pathology<sup>25</sup>. The seven novel loci were functionally annotated and fine-mapped to narrow down candidate causal genes (**Supplementary Results**). The functions of these candidate genes broadly align with the categories identified in the gene set analysis, with the addition of brain function, adult neurogenesis, protein-lipid interactions, and lipid efflux. Two of the novel loci have been

previously associated with frontotemporal dementia (FTD)<sup>26</sup>. This signal is not driven by the non-medically verified LOAD cases in the UKB proxy LOAD data (**Supplementary Results**), which suggests that this region is pleiotropic for FTD or contains separate causal variants within the same LD blocks. In one of these novel loci (locus 28), *ITGA2B* mapped to the LOAD-associated region based on six significant variants in high LD ( $R^2 > 0.9$ ) with the lead variant in locus 28 (rs708382). One of the significant variants within *ITGA2B* was a high CADD score (19.8) exonic variant (rs5911). *ITGA2B* is a target of an existing drug (Abciximab) and may be a potential target for drug repurposing. However, more evidence supports *GRN* as the causal gene for locus 28; the association signal colocalized with an eQTL for *GRN* in brain tissue and *GRN* is a known FTD gene<sup>27</sup>. Further replication and fine-mapping will be beneficial in understanding which gene is driving the association in locus 28. For all LOAD-associated loci, we used genomic position and eQTLs in relevant tissues to map variants to genes and we then identified drugs which target those genes (**Supplementary Table 6**). Such work can form the basis for identification of novel drug targets, supporting the efforts from the pharmaceutical industry to develop effective LOAD treatment.

Future work focusing on fine-mapping, generating larger QTL databases in more specific cells types, and incorporating other ancestries will improve the interpretability of associated loci. Our fine-mapping was able to successfully narrow down associated loci to sets of causal variants; however, regional interpretation was limited due to the reliance on a well matched but not perfectly matched reference panel. Our colocalisation analysis identified a candidate causal gene in 8 of the 38 loci and we expect that larger and more specific QTL datasets will improve the number of successful colocalization. Yao *et al.* (2020)<sup>28</sup> highlighted a need for higher sample size eQTL discovery and suggested that genes with smaller effect eQTLs are more likely to be causal for common traits. The identification of microglia, but not bulk brain tissue, as a cell/tissue type of interest in this study supported a finding in a recent single-cell epigenomic study<sup>29</sup>, which determined that investigating individual cell types will be more fruitful than bulk brain tissue for understanding the route from variant to LOAD pathology.

One important goal for LOAD GWAS is the identification of medically actionable information that can help in diagnosis or treatment in all populations. This study was limited in the ability to identify causal genes and in the applicability to non-European populations. Further study in non-European populations will improve the equity of genetic information and also help with fine-mapping of associated regions. Larger sample sizes of GWAS, epigenomic studies, and eQTL studies in all populations will improve identification and explanation of novel LOAD loci while increasing the applicability of these findings to a larger group of individuals. This could be accomplished by a push for facilitating data-sharing and global collaboration within the field of Alzheimer's disease genetics. The current work provided genetic support for the role of immune cells, microglia, and eQTLs in LOAD, identified novel LOAD-associated regions, and highlighted the importance of collaboration to discern the biological process that mediate LOAD pathology.

## URLs

UK Biobank, <http://ukbiobank.ac.uk>; FUMA software, <http://fuma.ctglab.nl>; MAGMA software, <http://ctg.cncr.nl/software/magma>; mvGWAMA and effective sample size calculation, <https://github.com/Kyoko-wtnb/mvGWAMA>; LD Score Regression software, <https://github.com/bulik/ldsc>; LD Hub (GWAS summary statistics), <http://ldsc.broadinstitute.org/>; LD scores, <https://data.broadinstitute.org/alkesgroup/LDSCORE/>; NHGRI GWAS catalog, <https://www.ebi.ac.uk/gwas/>.

## Acknowledgements

We thank the research participants from 23andMe who made this study possible. Members of the 23andMe Research Team are: Michelle Agee, Stella Aslibekyan, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, Katarzyna Bryc, Emily Bullis, Briana Cameron, Daniella Coker, Gabriel Cuellar Partida, Devika Dhamija, Sayantan Das, Sarah L. Elson, Teresa Filshstein, Kipper Fletez-Brant, Pierre Fontanillas, Will Freyman, Pooja M. Gandhi, Barry Hicks, David A. Hinds, Karen E. Huber, Ethan M. Jewett, Yunxuan Jiang, Aaron Kleinman, Katelyn Kukar, Vanessa Lane, Keng-Han Lin, Maya Lowe, Marie K. Luff, Jennifer C. McCreight, Matthew H. McIntyre, Kimberly F. McManus, Steven J. Micheletti, Meghan E. Moreno, Joanna L. Mountain, Sahar V. Mozaffari, Priyanka Nandakumar, Elizabeth S. Noblin, Jared O'Connell, Aaron A. Petrakovitz, G. David Poznik, Morgan Schumacher, Anjali J. Shastri, Janie F. Shelton, Jingchunzi Shi, Suyash Shringarpure, Chao Tian, Vinh Tran, Joyce Y. Tung, Xin Wang, Wei Wang, Catherine H. Weldon, and Peter Wilton.

IGAP: We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips was funded by the French National Foundation on Alzheimer's disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD/PERADES was supported by the Medical Research Council (Grant n° 503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.

HUNT: The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping was financed by the National Institute of health (NIH), University of Michigan, The Norwegian Research council, and Central Norway Regional Health Authority and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU). The genotype quality control and imputation has been conducted by the K.G. Jebsen center for genetic epidemiology, Department of public health and nursing, Faculty of medicine and health sciences, Norwegian University of Science and Technology (NTNU).

The authors would like to thank the Norwegian Dementia Genetics Network (DemGene). This work was supported by the Research Council of Norway (RCN; 248980, 248778, 223273), Norwegian Regional Health Authorities, Norwegian Health Association and EU JPND: PMI-AD. This work was supported by the National Institutes of Health, National Institute on Aging R01 AG08724, R01 AG17561, R01 AG028555, and R01 AG060470.



Thank you to all the participants included in this study including the participants from FinnGen, GR@CE, IGAP, UKB, DemGene, TwinGene, STSA, Gothenburg, ANMmerge, BioVU, 23andMe, HUNT, and deCODE.

AZ was supported by the Swedish Alzheimer Foundation (AF-930582, AF-646061, AF-741361), Stiftelsen Demensfonden, Magnus Bergvalls Stiftelse, Stiftelsen för Gamla Tjänarinnor, and Stiftelsen Handlanden Hjalmar Svenssons Forskningsfond. IS was supported by the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF 716681), the Swedish Research Council (no 11267, 825-2012-5041, 2013-8717, 2015-02830, 2017-00639, 2019-01096), Swedish Research Council for Health, Working Life and Welfare (no 2001-2646, 2001-2835, 2001-2849, 2003-0234, 2004-0150, 2005-0762, 2006-0020, 2008-1229, 2008-1210, 2012-1138, 2004-0145, 2006-0596, 2008-1111, 2010-0870, 2013-1202, 2013-2300, 2013-2496), Swedish Brain Power, Hjärnfonden, Sweden (FO2016-0214, FO2018-0214, FO2019-0163), the Alzheimer's Association Zenith Award (ZEN-01-3151), the Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159), the Alzheimer's Association (IIRG-03-6168, IIRG-09-131338) and the Bank of Sweden Tercentenary Foundation. SK was supported by the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-81392, ALF GBG-771071), the Swedish Alzheimer Foundation (AF-842471, AF-737641), and the Swedish Research Council (2019-02075). MW was supported by the Swedish Research Council 2016-01590. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. KB was supported by the Swedish Research Council (2017-00915) and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-715986). IKK receives funding from Swedish Research Council for Health, Working Life and Welfare (2018-01201) and the National Institutes of Health R01AG060470. NLP receives funding from the National Institutes of Health Grants No. R01AG059329, R01AG060470. CAR receives funding from the National Institutes of Health (NIH) including RF1AG058068, R01AG060470, R01AG059329, R01AG050595, and R01AG046938.

This work was funded by The Netherlands Organization for Scientific Research (NWO VICI 453-14-005), NWO Gravitation: BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (Grant No. 024.004.012), and a European Research Council advanced grant (Grant No, ERC-2018-AdG GWAS2FUNC 834057). The analyses were carried out on the Genetic Cluster Computer, which is financed by the Netherlands Scientific Organization (NWO: 480-05-003), by the VU University, Amsterdam, The Netherlands, and by the Dutch Brain Foundation, and is hosted by the Dutch National Computing and Networking Services SurfSARA.

## Competing Interests Statement

HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain

Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. OAA is a consultant to HealthLytix, and received speaker's honorarium from Lundbeck and Sunovion. All other authors declare no financial interests or potential conflicts of interest.

## Author contributions

DP and OAA conceived of the study. DPW performed the analyses. IEJ, JES, DP and OAA supervised analyses. DPW wrote the first draft of the manuscript. All authors contributed data and/or analyzed data and all authors critically reviewed the paper.

## Data Availability Statement

Access to raw data can be requested via the Psychiatric Genomics Data Access portal (<https://www.med.unc.edu/pgc/shared-methods/open-source-philosophy/>), UKBiobank, or 23andme. Summary statistics excluding 23andMe will be made available upon publication from [https://ctg.cncr.nl/software/summary\\_statistics](https://ctg.cncr.nl/software/summary_statistics). Access to the full set including 23andme results can be obtained upon completion of a Data Transfer Agreement that protects the privacy of 23andMe participants. Please visit <https://research.23andme.com/dataset-access/> to initiate a request. Summary statistics of the primary microglia eQTLs are also available from EGA (Accession ID: EGAD00001005736).

## References

1. Winblad, B. *et al.* Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet. Neurol.* **15**, 455–532 (2016).
2. Zhang, Q. *et al.* Risk prediction of late-onset Alzheimer's disease implies an oligogenic architecture. *Nat. Commun.* **11**, 4799 (2020).
3. Holland, D. *et al.* Beyond SNP heritability: Polygenicity and discoverability of phenotypes estimated with a univariate Gaussian mixture model. *PLOS Genet.* **16**, e1008612 (2020).
4. Bacigalupo, I. *et al.* A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe: Estimates from the Highest-Quality Studies Adopting the DSM IV Diagnostic Criteria. *J. Alzheimers. Dis.* **66**, 1471–1481 (2018).
5. DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of Alzheimer's disease. *Mol. Neurodegener.* **14**, 32 (2019).
6. Gatz, M. *et al.* Heritability for Alzheimer's disease: the study of dementia in Swedish twins. *J. Gerontol. A. Biol. Sci. Med. Sci.* **52**, M117-25 (1997).
7. Gatz, M. *et al.* Role of genes and environments for explaining Alzheimer disease. *Arch. Gen. Psychiatry* **63**, 168–174 (2006).
8. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat. Genet.* **51**, 404–413 (2019).
9. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–375 (2012).
10. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

11. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
12. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2016).
13. Lambert, J.-C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat. Genet.* **45**, 1452–1458 (2013).
14. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779 (2015).
15. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLOS Comput. Biol.* **11**, e1004219 (2015).
16. Watanabe, K., Umićević Mirkov, M., de Leeuw, C. A., van den Heuvel, M. P. & Posthuma, D. Genetic mapping of cell type specificity for complex traits. *Nat. Commun.* **10**, 3222 (2019).
17. Prodan, C. I. *et al.* Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. *Neurology* **76**, 247–252 (2011).
18. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *PLOS Genet.* **10**, e1004383 (2014).
19. Holler, C. J. *et al.* Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofibrillary tangle pathology. *J. Alzheimers. Dis.* **42**, 1221–1227 (2014).
20. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
21. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B (Statistical Methodol.* **n/a**, (2020).
22. Kundaje, A. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015).
23. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–D894 (2018).
24. Liu, J. Z., Erlich, Y. & Pickrell, J. K. Case-control association mapping by proxy using family history of disease. *Nat. Genet.* **49**, 325–331 (2017).
25. Schwabe, T., Srinivasan, K. & Rhinn, H. Shifting paradigms: The central role of microglia in Alzheimer’s disease. *Neurobiol. Dis.* **143**, 104962 (2020).
26. Ciani, M., Benussi, L., Bonvicini, C. & Ghidoni, R. Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. *Front. Neurosci.* **13**, 506 (2019).
27. Greaves, C. V & Rohrer, J. D. An update on genetic frontotemporal dementia. *J. Neurol.* **266**, 2075–2086 (2019).
28. Yao, D. W., O’Connor, L. J., Price, A. L. & Gusev, A. Quantifying genetic effects on disease mediated by assayed gene expression levels. *Nat. Genet.* **52**, 626–633 (2020).
29. Corces, M. R. *et al.* Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer’s and Parkinson’s diseases. *Nat. Genet.* **52**, 1158–1168 (2020).

## Figures

**Figure 1:** A Manhattan plot of the meta-analysis results highlighting 38 loci, including 7 novel regions. Only variants with a  $P < 0.0005$  are displayed. The *APOE* region cannot be fully observed because the y-axis is limited to the top variant in the second most significant locus,  $-\log_{10}(1 \times 10^{-60})$ , in order to display the less significant variants. The red line represents genome wide significance ( $5 \times 10^{-8}$ ). The novel loci are highlighted in green and indicated by the assigned gene name.

**Figure 2:** The enrichment and depletion of functional consequence annotations within the credible causal variants compared to the mapping region identified 8 significant annotations. The y-axis represents the proportion of variants within the credible causal variants that can be given that annotation. The annotation proportions do not add up to 1 because one variant can have multiple annotations. The colour of the bars represents the odds ratio (OR) from a Fisher's exact test comparing counts of annotations in the credible causal variants versus counts of annotations in the rest of the mapping region. The stars represent OR which are significantly different from 1.

Figure 1





Figure 2



## Tables

**Table 1:** The 38 genomic risk loci identified from 90,338 (46,613 proxy) cases and 1,036,225 (318,246 proxy) controls. The novel loci are highlighted in bold. The genes were assigned based on colocalization results, fine-mapping results, and previous literature.

**Table 1**

Genomic Locus	Gene	Position (GRCh37)	Lead variant	A1	A1 frequency	BETA	SE	P	N
1	<b>AGRN</b>	1:985377	<b>rs113020870</b>	T	<b>0.0041</b>	<b>0.069</b>	<b>0.013</b>	<b>3.83x10<sup>-8</sup></b>	<b>776379</b>
2	CR1	1:207750568	rs679515	C	0.82	-0.022	0.0021	2.42x10 <sup>-25</sup>	762176
3	<b>FHL2</b>	2:106235428	<b>rs115186657</b>	<b>C</b>	<b>0.0035</b>	<b>0.080</b>	<b>0.014</b>	<b>1.33x10<sup>-8</sup></b>	<b>727537</b>
4	BIN1	2:127891427	rs4663105	C	0.41	0.022	0.0014	3.92x10 <sup>-58</sup>	1078540
5	INPPD5	2:234082577	rs7597763	C	0.45	0.0092	0.0016	4.65x10 <sup>-9</sup>	819541
6	CLNK	4:11014822	rs4504245	G	0.79	-0.012	0.0017	5.23x10 <sup>-12</sup>	1080458
7	<b>TNIP1</b>	5:150432388	<b>rs871269</b>	T	<b>0.32</b>	<b>-0.0088</b>	<b>0.0014</b>	<b>1.37x10<sup>-9</sup></b>	<b>1089904</b>
8	<b>HAVCR2</b>	5:156526331	<b>rs6891966</b>	<b>G</b>	<b>0.77</b>	<b>0.0099</b>	<b>0.0016</b>	<b>7.91x10<sup>-10</sup></b>	<b>1089230</b>
9	HLA-DRB1	6:32583813	rs1846190	A	0.30	-0.013	0.0018	2.66x10 <sup>-14</sup>	754040
10	TREM2	6:40942196	rs187370608	G	0.997	-0.16	0.015	1.26x10 <sup>-25</sup>	791668
11	CD2AP	6:47552180	rs9369716	T	0.27	0.013	0.0016	1.70x10 <sup>-17</sup>	1052285
12	<b>TMEM106B</b>	7:12268758	<b>rs5011436</b>	<b>C</b>	<b>0.41</b>	<b>-0.0081</b>	<b>0.0014</b>	<b>2.70x10<sup>-9</sup></b>	<b>1123678</b>
13	ZCWPW1	7:99932049	rs7384878	T	0.69	0.012	0.0015	9.41x10 <sup>-16</sup>	1084138
14	EPHA1	7:143104331	rs3935067	G	0.62	-0.0091	0.0014	4.69x10 <sup>-11</sup>	1117025
15	CLU	8:27466315	rs1532278	T	0.39	-0.013	0.0014	1.57x10 <sup>-22</sup>	1126563
16	SHARPIN	8:145108151	rs61732533	G	0.95	-0.018	0.0031	3.14x10 <sup>-9</sup>	1122653
17	ECHDC3	10:11718713	rs7912495	G	0.46	0.010	0.0013	7.68x10 <sup>-15</sup>	1120367
18	CCDC6	10:61738152	rs7902657	T	0.54	0.0074	0.0013	3.68x10 <sup>-8</sup>	1126388
19	MADD	11:47380340	rs3740688	T	0.54	0.0077	0.0013	8.78x10 <sup>-9</sup>	1123185
20	MS4A6A	11:60021948	rs1582763	G	0.62	0.016	0.0014	3.40x10 <sup>-33</sup>	1125804
21	PICALM	11:85800279	rs561655	G	0.35	-0.015	0.0014	1.24x10 <sup>-26</sup>	1126563
22	SORL1	11:121435587	rs11218343	T	0.96	0.027	0.0036	1.33x10 <sup>-13</sup>	1125100
23	FERMT2	14:53298853	rs7146179	G	0.89	-0.014	0.0022	6.99x10 <sup>-11</sup>	1089904
24	SLC24A4	14:92938855	rs12590654	G	0.67	0.012	0.0014	6.63x10 <sup>-17</sup>	1116967
25	ADAM10	15:59057023	rs602602	T	0.70	0.011	0.0015	6.22x10 <sup>-15</sup>	1124268
26	APH1B	15:63569902	rs117618017	T	0.13	0.015	0.0022	7.00x10 <sup>-12</sup>	889854
27	CHRNE	17:4969940	rs7209200	T	0.33	0.0078	0.0014	3.18x10 <sup>-8</sup>	1125637
28	<b>GRN</b>	17:42442344	<b>rs708382</b>	T	<b>0.61</b>	<b>-0.0082</b>	<b>0.0014</b>	<b>1.98x10<sup>-9</sup></b>	<b>1125622</b>
29	ABI3	17:47450775	rs28394864	G	0.54	-0.0085	0.0014	4.90x10 <sup>-10</sup>	1084218
30	AC004687.2	17:56409089	rs2632516	G	0.54	0.0084	0.0014	7.46x10 <sup>-10</sup>	1082451
31	ACE	17:61545779	rs6504163	T	0.61	0.0085	0.0014	1.23x10 <sup>-9</sup>	1083145



32	<i>ABCA7</i>	19:1050874	rs12151021	G	0.68	-0.011	0.0015	$2.81 \times 10^{-15}$	1082434
33	<i>APOE</i>	19:45410444	rs769450	G	0.60	0.049	0.0014	$1.02 \times 10^{-289}$	1126563
34	<b><i>NTN5</i></b>	19:49213504	<b>rs2452170</b>	<b>G</b>	<b>0.47</b>	<b>-0.0077</b>	<b>0.0014</b>	<b><math>1.72 \times 10^{-8}</math></b>	<b>1088626</b>
35	<i>CD33</i>	19:51737991	rs1354106	G	0.37	-0.011	0.0017	$2.21 \times 10^{-10}$	716038
36	<i>KIR3DL2</i>	19:54825174	rs1761461	C	0.49	0.0081	0.0013	$1.56 \times 10^{-9}$	1116336
37	<i>CASS4</i>	20:54995699	rs6069737	T	0.083	-0.020	0.0025	$6.73 \times 10^{-16}$	1087703
38	<i>APP</i>	21:27520931	rs2154482	T	0.44	-0.0083	0.0013	$7.66 \times 10^{-10}$	1124606

# Online Methods

## Dataset Processing

### Participants

The data from the participants in this study were obtained from freely available summary statistics (N=145,339) and from genotype level data (N=981,224). Seven new cohorts were obtained since our previous analysis<sup>1</sup> (as well as an increased deCODE sample), these cohorts contain 12,968 new cases and 488,616 new controls. An overview of the cohorts is available in Supplementary Table 1. Full description of each dataset, the quality control (QC) procedures, and the analysis protocol are available in the Supplementary Methods. In short, each dataset underwent initial QC, imputation, logistic/linear regression, and post-regression QC of the summary statistics using EasyQC<sup>2</sup>. If necessary, the data were converted to build GRCh37 before QC using the UCSC LiftOver tool<sup>3</sup>. During post-regression QC, each dataset was matched to the HRC or 1KG reference panel and variants with absolute allele frequency differences > 0.2 compared to the reference panel were removed. Variants with an imputation quality score < 0.8, MAC < 6, N < 30, or absolute beta or SE > 10 were removed. Low minor allele frequency (MAF) variants were removed; low MAF<sup>4</sup> was defined as  $< \frac{1}{\sqrt{2 \times N}}$ .

### Meta-analysis

All datasets were meta-analysed using mv-GWAMA, a sample size weighted method previously developed in Jansen *et al.* (2019)<sup>1</sup>. The option to account for overlapping individuals was not utilized because no datasets were expected to contain overlapping samples and the estimates of overlapping samples (genetic covariance intercepts) were unreliable due to low heritability of the datasets. The resulting Z-scores from the meta-analysis were converted to effect estimates (BETA) and standard errors (SE) using these formulae<sup>5</sup>:

$$BETA = \frac{Z}{\sqrt{(2 \times MAF \times (1 - MAF)) \times (N + Z^2)}}$$
$$SE = \frac{1}{\sqrt{(2 \times MAF \times (1 - MAF)) \times (N + Z^2)}}$$

For a few (31) extremely significant *APOE* region variants, Z-scores could not be estimated so BETA and SE were calculated from a weighted average of the datasets which included those variants.

### Genomic risk loci definition

We used FUMA v1.3.6<sup>6</sup> to annotate and functionally map variants included in the meta-analysis. Genomic risk loci were defined around significant variants ( $< 5 \times 10^{-8}$ ); the genomic risk loci included all variants correlated ( $R^2 > 0.6$ ) with the most significant variant. The correlation estimates were defined using 1KG European reference information. The 1KG European reference panel was chosen over the UKB<sup>7</sup> 10K reference panel because the meta-analysis included individuals from a range of European ancestries and this diversity would be better reflected in the 1KG European sample than the primarily British UKB sample. Genomic risk loci within 250Kb of each other are incorporated into the same locus.

Novel associated genomic risk loci are loci which do not overlap with variants identified as significant in previous studies of LOAD<sup>1,8-14</sup>. High and lower confidence novel loci are defined based on how well supported the lead variant is with other variants in LD.

Variants with very few (<5) supporting variants are described as lower confidence. The edge of one of the novel loci (locus 34) was located within 2.7Mb of the edge of the *APOE* locus; in order to determine whether this was an independent locus GCTA-COJO<sup>15</sup> was used to identify the independently associated SNPs within the *APOE* locus. The UKB participants were used as a reference panel to determine LD in the GCTA-COJO analysis. The independently associated SNPs were then conditioned on in an association analysis of the joint regions. The lead variant of locus 34 (rs2452170; GRCh37: 19:49213504) was still significant after conditioning on all independently associated variants within the *APOE* region (19:45000000-47000000).

## Heritability and genetic correlation

Linkage disequilibrium score (LDSC) regression<sup>16</sup> was used to estimate the heritability of the combined LOAD and proxy LOAD meta-analysis. LDSC<sup>17</sup> was also used to determine the genetic correlation between a meta-analysis of datasets with clinically-diagnosed LOAD cases, and the UKB proxy LOAD dataset. Pre-calculated LD scores for LDSC were derived from the 1KG European reference population ([https://data.broadinstitute.org/alkesgroup/LDSCORE/eur\\_w\\_ld\\_chr.tar.bz2](https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2)). Heritability estimates were converted to a liability scale using the LOAD population prevalence of 0.05 and a sample prevalence of 0.0802. Heritability and genetic correlation estimates were calculated using HapMap3 variants only and the *APOE* region was excluded (GRCh37: 19:42353608-47713504). Further genetic correlations were determined using LDhub<sup>18</sup>, where all 855 traits were tested using the HapMap3 variants ([http://ldsc.broadinstitute.org/static/media/w\\_hm3.noMHC.snplist.zip](http://ldsc.broadinstitute.org/static/media/w_hm3.noMHC.snplist.zip)).

## Gene-based and gene set analyses

Genome-wide gene association analysis was performed using MAGMA v1.08<sup>19</sup>. All variants in the GWAS outside of the MHC region (GRCh37: 6:28,477,797-33,448,354) that positionally map within one of the 19,019 protein coding genes were included to estimate the significance value of that gene. MAGMA gene set analysis was performed where variants map to 15,496 gene-sets from the MSigDB v7.0 database<sup>20</sup>. Forward selection of significantly associated gene-sets was performed using MAGMA v1.08 conditional analysis<sup>21</sup>. Initially the most significant gene-set was selected as a covariate and the remaining 24 gene-sets were analysed. The most significant gene-set from this conditional analysis was added as a covariate in addition to the previous gene-set and a new analysis was run. This process was repeated until no gene-set met the significance threshold ( $P < 3.23 \times 10^{-6}$ ). MAGMA tissue specificity analysis was performed in FUMA using 30 general tissue type gene expression profiles (from GTEx v8).

FUMA cell type specificity analysis<sup>22</sup> utilises the MAGMA gene association results to identify cell types enriched in expression of trait associated genes. We focused on brain and immune related cell types with the inclusion of pancreas as a control, therefore selecting the following scRNA-seq datasets: Allen\_Human\_LGN\_level1<sup>23</sup>, Allen\_Human\_LGN\_level2<sup>23</sup>, Allen\_Human\_MTG\_level1<sup>23</sup>, Allen\_Human\_MTG\_level2<sup>23</sup>, DroNc\_Human\_Hippocampus<sup>24</sup>, DroNc\_Mouse\_Hippocampus<sup>24</sup>, GSE104276\_Human\_Prefrontal\_cortex\_all\_ages<sup>25</sup>, GSE67835\_Human\_Cortex<sup>26</sup>, GSE81547\_Human\_Pancreas<sup>27</sup>, Linnarsson\_GSE101601\_Human\_Temporal\_cortex<sup>28</sup>, MouseCellAtlas\_all<sup>29</sup>, PBMC\_10x\_68k<sup>30</sup>, and PsychENCODE\_Adult<sup>31</sup>. Within-dataset conditional analyses results were reported to indicate which single cells are most likely to be disease relevant.

## Gene mapping

The individual genomic risk loci were mapped to genes using FUMA v1.3.6<sup>6</sup> using positional mapping and eQTL mapping. For positional mapping, all variants within 10Kb of a gene in the genomic risk locus were assigned to that gene. For eQTL mapping, variants were mapped to genes based on significant eQTL interactions in a collection of immune and brain tissues. Brain tissue eQTLs were used due to importance of brain tissue in LOAD pathology and immune tissue/cell eQTLs were used for gene mapping because MAGMA tissue specificity analysis highlighted immune tissues as tissues of interest. The brain and immune tissues eQTLs used for mapping were: Alasoo naive macrophage<sup>32</sup>, BLUEPRINT monocyte<sup>33</sup>, BLUEPRINT neutrophil<sup>33</sup>, BLUEPRINT T-cell<sup>33</sup>, BrainSeq Brain<sup>34</sup>, CEDAR B-cell<sup>35</sup>, CEDAR monocyte, CEDAR neutrophil<sup>35</sup>, CEDAR T-cell<sup>35</sup>, Fairfax B-cell<sup>36</sup>, Fairfax naive monocyte<sup>37</sup>, GENCORD T-cell<sup>38</sup>, Kasela CD4 T-cell<sup>39</sup>, Kasela CD8 T-cell<sup>39</sup>, Lepik Blood<sup>40</sup>, Naranbhai neutrophil<sup>41</sup>, Nedelec macrophage<sup>42</sup>, Quach monocyte<sup>43</sup>, Schwartzentruber sensory neuron<sup>44</sup>, TwinsUK blood<sup>45</sup>, PsychENCODE brain<sup>31</sup>, eQTLGen blood cis and trans<sup>46</sup>, BloodQTL blood<sup>47</sup>, BIOS Blood<sup>48</sup>, xQTLServer blood<sup>49</sup>, CommonMind Consortium brain<sup>50</sup>, BRAINEAC brain<sup>51</sup>, GTEX v8 lymphocytes, brain, spleen, and whole blood. FUMA was also used to identify potential drug targets from the 989 mapped genes using Drugbank<sup>52</sup>.

## Colocalization

All variants within 1.5Mb of the lead variant of each genomic risk loci were used in the colocalization analysis. The GWAS data and eQTL data were trimmed so that all variants overlap. Colocalization was performed per gene using coloc.abf from the Coloc R package<sup>53</sup>. Default priors were used for prior probability of association with the GWAS data and eQTL data. The prior probability of colocalization was set as  $1 \times 10^{-6}$  as recommended<sup>54</sup>. In all analyses BETA,  $SE^2$  (variance), case prevalence, and sample size from the GWAS data were used. In colocalization analyses with all tissues except microglia, nominal  $P$ , sample size, and minor allele frequency from the eQTL data were used. BETA,  $SE^2$  (variance), MAF, and sample size from the microglia eQTL data were used for colocalization. Colocalizations with a posterior probability  $> 0.8$  were considered successful colocalizations. eQTL data from all tissues except microglia were obtained from the eQTL catalogue<sup>55</sup>. The microglia data was obtained from Young *et al.* (2019)<sup>56</sup>.

## Fine-mapping

Fine-mapping was performed with SusieR v0.9.1<sup>57</sup> and FINEMAP v1.4<sup>58</sup> on all variants within 1.5Mb of the lead variant of each genomic risk loci. The *APOE* and *HLA-DRB1* (MHC) regions were excluded from fine-mapping due to the complicated LD structure. Chromosome 6 was excluded from fine-mapping because no associations outside of the *HLA-DRB1* region existed and the two loci on chromosome 19 between 19:2550874-47713504 (GRCh37) were also excluded because they were within the *APOE* locus. Both SusieR and FINEMAP were used because it is recommended to use multiple fine-mapping methods in order to find consensus and increase the robustness of the results<sup>59</sup>. The sample size of the fine-mapping reference panel should be proportional to the sample size of the data being fine-mapped. A good-sized reference panel is 10% to 20% the sample size of the data<sup>60</sup>. UKB data was used as a reference panel for the fine-mapping because it had the largest sample size of the available reference panels and was the only available European reference panel to fulfill the criteria for a good-sized reference panel. In the SusieR analysis the reference panel was ~10% the size of the GWAS data. In the FINEMAP analysis the reference panel was ~40% the size of the GWAS data. The difference in size is due to FINEMAP allowing for individuals who have some genotypes missing to be included in the LD calculations from the reference panel. For FINEMAP, an LD matrix was generated using LDSTORE v2.0<sup>60</sup> using 387,533 individuals included in the UKB. For SusieR, an LD matrix was generated using 100,000 individuals in R v3.4.3<sup>61</sup>. The 100,000 individuals were chosen for each locus as the top 100,000 people with the most genotyped variants in the locus in

order to maintain the highest number of variants in the fine-mapping. Only the top 100,000 were chosen for computational feasibility and in order to maintain as many variants as possible while having a large reference panel. In both SusieR and FINEMAP, the meta-analysis data was trimmed to match the variants included in the LD reference. The maximum number of causal variants in the region was set to 10 in both methods. To generate the 95% FINEMAP confidence set, the variants included in the top N models in the configuration file were aggregated until the summed probability of the models reached 0.95. The SusieR 95% credible sets were generated by SusieR using default settings. The allele frequency in the UKB data and meta-analysis data of all the variants in the fine-mapping analyses were compared to identify outliers. No variants included in the confidence set or credible set had an allele frequency difference > 0.2.

## Functional enrichment of significant association signals

All enrichment analyses were performed using a Fisher's exact test (`fisher.test`) implemented in R 4.0.1<sup>61</sup>. For enrichment of genomic risk loci, all variants within the genomic risk loci were compared to all other variants present in the meta-analysis. For enrichment of the credible causal variants, all variants present in the 95% confidence set from FINEMAP and all variants in the credible set from successful SusieR analyses were compared to all other variants included in the mapping region.

Enrichment of active chromatin was performed using ROADMAP Core 15-state model annotation<sup>62</sup> obtained from <https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.mnemonics.bedFiles.tgz>. For each of the 127 cell types, all variants within the analysis were annotated with one of the 15 states using the R package Genomic Ranges<sup>63</sup>. All variants annotated with a state < 8 were defined as being within active chromatin. The enrichment of active chromatin within the specified region was performed for each of the cell types and the resulting *P*-values were corrected for 127 tests using Bonferroni correction.

Enrichment of eQTLs was performed using all tissues in the GTEx v8 dataset. Significant variant-gene pairs were downloaded from [https://storage.googleapis.com/gtex\\_analysis\\_v8/single\\_tissue\\_qtl\\_data/GTex\\_Analysis\\_v8\\_eQTL.tar](https://storage.googleapis.com/gtex_analysis_v8/single_tissue_qtl_data/GTex_Analysis_v8_eQTL.tar). The significant eQTL variants were overlapped with the variants included in the enrichment analysis and eQTL counts within and outside the specified regions were generated for Fisher's exact tests. The resulting *P*-values were corrected for the inclusion of 47 tissues from the GTEx v8 dataset using Bonferroni correction. The enrichment plots were generated using the R package ggplot2<sup>64</sup>.

Enrichment of functional consequences was performed using VEP<sup>65</sup> and ANNOVAR<sup>66</sup>. All of the variants outside of the MHC region (GRCh37: 6:28,477,797-33,448,354) in the meta-analysis and the genomic risk loci variants were annotated using ANNOVAR and FASTA sequences for all annotated transcripts in RefSeq Gene<sup>67</sup>. The counts of each functional consequence in the genomic risk loci were compared to all variants outside of the loci. The significance threshold for the annotation enrichment was adjusted for the 11 tests performed ( $P < 0.0045$ ). The mapping regions from the fine-mapping analysis were annotated using VEP to identify functional consequences and CADD score<sup>68</sup> for exonic variants. The counts of each functional consequence in the credible causal variants were compared to the variants in the mapping region. Exonic variants were annotated with a CADD score and counts of credible causal variants with a CADD score >15 were compared to all other variants in the mapping region. The CADD score threshold was chosen because 15 was the median CADD score for the median value for all possible

canonical splice site changes and non-synonymous variants in CADD v1.0. The significance threshold was adjusted for the 12 tests performed for the annotation enrichment ( $P < 0.0042$ ).

## Methods-Only References

1. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat. Genet.* **51**, 404–413 (2019).
2. Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192–1212 (2014).
3. Kuhn, R. M., Haussler, D. & Kent, W. J. The UCSC genome browser and associated tools. *Brief. Bioinform.* **14**, 144–161 (2013).
4. Ionita-Laza, I., Lee, S., Makarov, V., Buxbaum, J. D. & Lin, X. Sequence Kernel Association Tests for the Combined Effect of Rare and Common Variants. *Am. J. Hum. Genet.* **92**, 841–853 (2013).
5. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
6. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
7. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779 (2015).
8. Liu, P.-P., Xie, Y., Meng, X.-Y. & Kang, J.-S. History and progress of hypotheses and clinical trials for Alzheimer's disease. *Signal Transduct. Target. Ther.* **4**, 29 (2019).
9. Lambert, J.-C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat. Genet.* **45**, 1452–1458 (2013).
10. Marioni, R. E. *et al.* GWAS on family history of Alzheimer's disease. *Transl. Psychiatry* **8**, 99 (2018).
11. Desikan, R. S. *et al.* Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. *PLOS Med.* **14**, e1002258 (2017).
12. Jun, G. *et al.* A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol. Psychiatry* **21**, 108–117 (2016).
13. de Rojas, I. *et al.* Common variants in Alzheimer's disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores. *medRxiv* 19012021 (2020). doi:10.1101/19012021
14. Schwartzenuber, J. *et al.* Genome-wide meta-analysis, fine-mapping, and integrative prioritization identify new Alzheimer's disease risk genes. *medRxiv* 2020.01.22.20018424 (2020). doi:10.1101/2020.01.22.20018424
15. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–375 (2012).
16. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
17. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
18. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2016).
19. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLOS Comput. Biol.* **11**, e1004219 (2015).
20. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* **1**, 417–425 (2015).

21. de Leeuw, C. A., Stringer, S., Dekkers, I. A., Heskes, T. & Posthuma, D. Conditional and interaction gene-set analysis reveals novel functional pathways for blood pressure. *Nat. Commun.* **9**, 3768 (2018).
22. Watanabe, K., Umićević Mirkov, M., de Leeuw, C. A., van den Heuvel, M. P. & Posthuma, D. Genetic mapping of cell type specificity for complex traits. *Nat. Commun.* **10**, 3222 (2019).
23. Hodge, R. D. *et al.* Conserved cell types with divergent features in human versus mouse cortex. *Nature* **573**, 61–68 (2019).
24. Habib, N. *et al.* Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat. Methods* **14**, 955–958 (2017).
25. Zhong, S. *et al.* A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. *Nature* **555**, 524–528 (2018).
26. Darmanis, S. *et al.* A survey of human brain transcriptome diversity at the single cell level. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 7285–7290 (2015).
27. Enge, M. *et al.* Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns. *Cell* **171**, 321-330.e14 (2017).
28. Hochgerner, H. *et al.* STRT-seq-2i: dual-index 5' single cell and nucleus RNA-seq on an addressable microwell array. *Sci. Rep.* **7**, 16327 (2017).
29. Han, X. *et al.* Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell* **172**, 1091-1107.e17 (2018).
30. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**, 14049 (2017).
31. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human brain. *Science* **362**, (2018).
32. Alasoo, K. *et al.* Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. *Nat. Genet.* **50**, 424–431 (2018).
33. Chen, L. *et al.* Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. *Cell* **167**, 1398-1414.e24 (2016).
34. Jaffe, A. E. *et al.* Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. *Nat. Neurosci.* **21**, 1117–1125 (2018).
35. Momozawa, Y. *et al.* IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. *Nat. Commun.* **9**, 2427 (2018).
36. Fairfax, B. P. *et al.* Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. *Nat. Genet.* **44**, 502–510 (2012).
37. Fairfax, B. P. *et al.* Innate Immune Activity Conditions the Effect of Regulatory Variants upon Monocyte Gene Expression. *Science (80-. ).* **343**, 1246949 (2014).
38. Gutierrez-Arcelus, M. *et al.* Passive and active DNA methylation and the interplay with genetic variation in gene regulation. *Elife* **2**, e00523 (2013).
39. Kasela, S. *et al.* Pathogenic implications for autoimmune mechanisms derived by comparative eQTL analysis of CD4+ versus CD8+ T cells. *PLOS Genet.* **13**, e1006643 (2017).
40. Lepik, K. *et al.* C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis. *PLOS Comput. Biol.* **13**, e1005766 (2017).
41. Naranbhai, V. *et al.* Genomic modulators of gene expression in human neutrophils. *Nat. Commun.* **6**, 7545 (2015).
42. Nédélec, Y. *et al.* Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. *Cell* **167**, 657-669.e21 (2016).
43. Quach, H. *et al.* Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. *Cell* **167**, 643-656.e17 (2016).
44. Schwartzenuber, J. *et al.* Molecular and functional variation in iPSC-derived sensory neurons. *Nat. Genet.* **50**, 54–61 (2018).
45. Buil, A. *et al.* Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. *Nat. Genet.* **47**, 88–91 (2015).

46. Vösa, U. *et al.* Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. *bioRxiv* 447367 (2018). doi:10.1101/447367
47. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).
48. Zhernakova, D. V *et al.* Identification of context-dependent expression quantitative trait loci in whole blood. *Nat. Genet.* **49**, 139–145 (2017).
49. Ng, B. *et al.* An xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome. *Nat. Neurosci.* **20**, 1418–1426 (2017).
50. Fromer, M. *et al.* Gene expression elucidates functional impact of polygenic risk for schizophrenia. *Nat. Neurosci.* **19**, 1442–1453 (2016).
51. Ramasamy, A. *et al.* Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat. Neurosci.* **17**, 1418–1428 (2014).
52. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* **46**, D1074–D1082 (2018).
53. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *PLOS Genet.* **10**, e1004383 (2014).
54. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. *PLOS Genet.* **16**, e1008720 (2020).
55. Kerimov, N. *et al.* eQTL Catalogue: a compendium of uniformly processed human gene expression and splicing QTLs. *bioRxiv* 2020.01.29.924266 (2020). doi:10.1101/2020.01.29.924266
56. Young, A. M. H. *et al.* A map of transcriptional heterogeneity and regulatory variation in human microglia. *bioRxiv* 2019.12.20.874099 (2019). doi:10.1101/2019.12.20.874099
57. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B (Statistical Methodol.* **n/a**, (2020).
58. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
59. Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal variants by statistical fine-mapping. *Nat. Rev. Genet.* **19**, 491–504 (2018).
60. Benner, C. *et al.* Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using Summary Statistics from Genome-wide Association Studies. *Am. J. Hum. Genet.* **101**, 539–551 (2017).
61. R Core Team. R: A Language and Environment for Statistical Computing. *R Foundation for Statistical Computing* (2017).
62. Kundaje, A. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015).
63. Lawrence, M. *et al.* Software for Computing and Annotating Genomic Ranges. *PLOS Comput. Biol.* **9**, e1003118 (2013).
64. Hadley Wickham. *ggplot2: Elegant Graphics for Data Analysis.* (Springer-Verlag New York, 2016).
65. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
66. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164–e164 (2010).
67. O'Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* **44**, D733–D745 (2016).
68. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–D894 (2018).